About Us

GeneCentric Company Overview

GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our approach applies our rT(I)ME Explorer Platform to parse the complexity of the tumor and the immune microenvironment and overall tumor biology to generate response  signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers, or predictive response signatures, for immune-based, targeted and other cancer therapeutics. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we can deploy the rT(I)ME Explorer Platform at all stages of the drug development cycle.


Kirk Beebe, PhD

Vice President of Discovery and Translational Science


Philippe Chemla, PhD, MBA

Chief Business Officer

James M Davison, PhD

Senior Translational Genomics Scientist

Jeff Burdine

Sr. Director Information Technology

Joel R. Eisner, PhD

Sr. Vice President - Clinical & Corporate Development

Felix Frueh, PhD

Genomics Application and Regulatory Expert Executive Partner, Opus Three Life Sciences

John Guo

John Guo, PhD

Senior Bioinformatics Scientist

Myla Lai-Goldman, MD

Founder & Executive Chairperson

Greg Mayhew, DrPH

Director of Bioinformatics

Mike Milburn

Michael V. Milburn, PhD

Chief Executive Officer and President

Joel Parker, PhD

Bioinformatics, RNA, and expression analysis expert Associate Professor, UNC-Chapel Hill

Paul Armistead, MD, PhD

Immunology, Hematologist and Antigen Expert Associate Professor of Medicine, UNC-Chapel Hill

Chenyqua Shepard, CPA

Vice President, Finance

Yoichiro Shibata, PhD

Senior Bioinformatics Scientist

Josh Uronis, PhD

Laboratory Director

Benjamin Vincent, MD

Hematologist and Immunogenomics Expert Assistant Professor of Medicine, UNC-Chapel Hill

Myla Lai-Goldman, MD

Founder & Executive Chairperson

Arnold J. Levine, Phd


Ellen Lubman


Mike Milburn

Michael V. Milburn, PhD

Chief Executive Officer and President

Charles M. Perou, PhD

Founder and Director

Clay Thorp


N. Hayes

David Neil Hayes, MD MPH MS

Observer and Founder

Making News: Our Latest Progress, Partnerships and Impact

GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squam ...


GeneCentric Therapeutics Announces the Appointment of Philippe Chemla, PhD, MBA, as Chief Business O ...


GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Bi ...